Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShanChol Safety and Immunogenicity in Bangladesh
NCT01042951Phase 2Completed
- Sponsor
- icddr,b
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cholera comparing ShanChol with Placebo (2 arms). Primary endpoint: Safety and Reactogenicity of orally administered killed, bivalent whole-cell cholera vaccine at 28 days. Started Jan 2010; status: completed.
02
Drugs
cholera vaccine (inactivated, oral)
03
Conditions
cholera
Beyond the preview
Go deeper on NCT01042951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01042951.